Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8497 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.8393 |
Intermediate Similarity |
NPD7228 |
Approved |
0.8171 |
Intermediate Similarity |
NPD8455 |
Phase 2 |
0.8086 |
Intermediate Similarity |
NPD1653 |
Approved |
0.8084 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.8011 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.8 |
Intermediate Similarity |
NPD8312 |
Approved |
0.8 |
Intermediate Similarity |
NPD8313 |
Approved |
0.7989 |
Intermediate Similarity |
NPD7240 |
Approved |
0.7989 |
Intermediate Similarity |
NPD7685 |
Pre-registration |
0.7964 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7964 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7964 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.795 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7882 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7874 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7874 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7829 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.7816 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7812 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.7784 |
Intermediate Similarity |
NPD37 |
Approved |
0.7759 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7751 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.774 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7688 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7684 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.768 |
Intermediate Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.7674 |
Intermediate Similarity |
NPD8127 |
Discontinued |
0.766 |
Intermediate Similarity |
NPD7680 |
Approved |
0.7627 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7564 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.7543 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7543 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7543 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7542 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.754 |
Intermediate Similarity |
NPD7237 |
Clinical (unspecified phase) |
0.7532 |
Intermediate Similarity |
NPD1613 |
Approved |
0.7532 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD7097 |
Phase 1 |
0.7486 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7485 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7416 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7399 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7333 |
Intermediate Similarity |
NPD8166 |
Discontinued |
0.7318 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.7312 |
Intermediate Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.7289 |
Intermediate Similarity |
NPD6190 |
Approved |
0.7278 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.7278 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.7273 |
Intermediate Similarity |
NPD3705 |
Approved |
0.7268 |
Intermediate Similarity |
NPD7090 |
Clinical (unspecified phase) |
0.7267 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7253 |
Intermediate Similarity |
NPD7549 |
Discontinued |
0.7229 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7215 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.7215 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.7205 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7188 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.7179 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7161 |
Intermediate Similarity |
NPD1091 |
Approved |
0.716 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.7143 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.7143 |
Intermediate Similarity |
NPD5058 |
Phase 3 |
0.7126 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7126 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7125 |
Intermediate Similarity |
NPD7095 |
Approved |
0.7099 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.7099 |
Intermediate Similarity |
NPD3620 |
Phase 2 |
0.7093 |
Intermediate Similarity |
NPD7458 |
Discontinued |
0.7078 |
Intermediate Similarity |
NPD1357 |
Approved |
0.7056 |
Intermediate Similarity |
NPD7852 |
Clinical (unspecified phase) |
0.7055 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.7048 |
Intermediate Similarity |
NPD5762 |
Approved |
0.7048 |
Intermediate Similarity |
NPD5763 |
Approved |
0.7045 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7037 |
Intermediate Similarity |
NPD6233 |
Phase 2 |
0.7024 |
Intermediate Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.7024 |
Intermediate Similarity |
NPD4110 |
Phase 3 |
0.7022 |
Intermediate Similarity |
NPD5494 |
Approved |
0.702 |
Intermediate Similarity |
NPD8151 |
Discontinued |
0.7018 |
Intermediate Similarity |
NPD6273 |
Approved |
0.7017 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7012 |
Intermediate Similarity |
NPD6653 |
Approved |
0.7006 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.6994 |
Remote Similarity |
NPD4140 |
Approved |
0.6989 |
Remote Similarity |
NPD3817 |
Phase 2 |
0.6989 |
Remote Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.6978 |
Remote Similarity |
NPD3751 |
Discontinued |
0.6975 |
Remote Similarity |
NPD6798 |
Discontinued |
0.6971 |
Remote Similarity |
NPD7945 |
Clinical (unspecified phase) |
0.6954 |
Remote Similarity |
NPD7028 |
Phase 2 |
0.6951 |
Remote Similarity |
NPD5124 |
Phase 1 |
0.6951 |
Remote Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.6951 |
Remote Similarity |
NPD5735 |
Approved |
0.6944 |
Remote Similarity |
NPD3787 |
Discontinued |
0.6944 |
Remote Similarity |
NPD6232 |
Discontinued |
0.6932 |
Remote Similarity |
NPD2977 |
Approved |
0.6932 |
Remote Similarity |
NPD2801 |
Approved |
0.6932 |
Remote Similarity |
NPD7819 |
Suspended |
0.6932 |
Remote Similarity |
NPD2978 |
Approved |
0.6919 |
Remote Similarity |
NPD7314 |
Clinical (unspecified phase) |
0.6915 |
Remote Similarity |
NPD8434 |
Phase 2 |
0.6908 |
Remote Similarity |
NPD5283 |
Phase 1 |
0.6897 |
Remote Similarity |
NPD5808 |
Clinical (unspecified phase) |
0.6889 |
Remote Similarity |
NPD6959 |
Discontinued |
0.6878 |
Remote Similarity |
NPD6842 |
Approved |
0.6878 |
Remote Similarity |
NPD6841 |
Approved |
0.6878 |
Remote Similarity |
NPD6843 |
Phase 3 |
0.6866 |
Remote Similarity |
NPD7783 |
Phase 2 |
0.6866 |
Remote Similarity |
NPD7782 |
Clinical (unspecified phase) |
0.6864 |
Remote Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.6864 |
Remote Similarity |
NPD1652 |
Phase 2 |
0.6864 |
Remote Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.686 |
Remote Similarity |
NPD7446 |
Clinical (unspecified phase) |
0.6857 |
Remote Similarity |
NPD4380 |
Phase 2 |
0.6853 |
Remote Similarity |
NPD7435 |
Discontinued |
0.6848 |
Remote Similarity |
NPD4340 |
Discontinued |
0.6842 |
Remote Similarity |
NPD7843 |
Approved |
0.6836 |
Remote Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.6835 |
Remote Similarity |
NPD1610 |
Phase 2 |
0.6828 |
Remote Similarity |
NPD7038 |
Approved |
0.6828 |
Remote Similarity |
NPD7039 |
Approved |
0.6826 |
Remote Similarity |
NPD5588 |
Approved |
0.6824 |
Remote Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.6818 |
Remote Similarity |
NPD7411 |
Suspended |
0.6818 |
Remote Similarity |
NPD7157 |
Approved |
0.6809 |
Remote Similarity |
NPD8053 |
Approved |
0.6809 |
Remote Similarity |
NPD8054 |
Approved |
0.6798 |
Remote Similarity |
NPD5402 |
Approved |
0.6789 |
Remote Similarity |
NPD7906 |
Approved |
0.6776 |
Remote Similarity |
NPD228 |
Approved |
0.6768 |
Remote Similarity |
NPD3764 |
Approved |
0.6766 |
Remote Similarity |
NPD4538 |
Approved |
0.6766 |
Remote Similarity |
NPD4536 |
Approved |
0.6766 |
Remote Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.6755 |
Remote Similarity |
NPD7312 |
Approved |
0.6755 |
Remote Similarity |
NPD7310 |
Approved |
0.6755 |
Remote Similarity |
NPD7313 |
Approved |
0.6755 |
Remote Similarity |
NPD7311 |
Approved |
0.6747 |
Remote Similarity |
NPD1933 |
Approved |
0.6746 |
Remote Similarity |
NPD6006 |
Clinical (unspecified phase) |
0.6746 |
Remote Similarity |
NPD6002 |
Phase 3 |
0.6746 |
Remote Similarity |
NPD1375 |
Discontinued |
0.6746 |
Remote Similarity |
NPD6004 |
Phase 3 |
0.6746 |
Remote Similarity |
NPD6003 |
Clinical (unspecified phase) |
0.6746 |
Remote Similarity |
NPD6005 |
Phase 3 |
0.6744 |
Remote Similarity |
NPD6783 |
Clinical (unspecified phase) |
0.6743 |
Remote Similarity |
NPD3686 |
Approved |
0.6743 |
Remote Similarity |
NPD3687 |
Approved |
0.6742 |
Remote Similarity |
NPD5563 |
Clinical (unspecified phase) |
0.6734 |
Remote Similarity |
NPD7871 |
Phase 2 |
0.6734 |
Remote Similarity |
NPD7870 |
Phase 2 |
0.6733 |
Remote Similarity |
NPD7874 |
Approved |
0.6733 |
Remote Similarity |
NPD7875 |
Clinical (unspecified phase) |
0.6732 |
Remote Similarity |
NPD5535 |
Approved |
0.6731 |
Remote Similarity |
NPD5536 |
Phase 2 |
0.6726 |
Remote Similarity |
NPD7033 |
Discontinued |
0.6725 |
Remote Similarity |
NPD3750 |
Approved |
0.6722 |
Remote Similarity |
NPD3749 |
Approved |
0.6722 |
Remote Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.672 |
Remote Similarity |
NPD7309 |
Approved |
0.6717 |
Remote Similarity |
NPD6823 |
Phase 2 |
0.6709 |
Remote Similarity |
NPD5125 |
Phase 3 |
0.6709 |
Remote Similarity |
NPD5126 |
Approved |
0.6708 |
Remote Similarity |
NPD8651 |
Approved |
0.6705 |
Remote Similarity |
NPD1511 |
Approved |
0.6701 |
Remote Similarity |
NPD6777 |
Approved |
0.6701 |
Remote Similarity |
NPD6781 |
Approved |
0.6701 |
Remote Similarity |
NPD6780 |
Approved |
0.6701 |
Remote Similarity |
NPD6778 |
Approved |
0.6701 |
Remote Similarity |
NPD6782 |
Approved |
0.6701 |
Remote Similarity |
NPD6776 |
Approved |
0.6701 |
Remote Similarity |
NPD6779 |
Approved |
0.6687 |
Remote Similarity |
NPD1608 |
Approved |
0.6687 |
Remote Similarity |
NPD1558 |
Phase 1 |
0.6686 |
Remote Similarity |
NPD5403 |
Approved |
0.6685 |
Remote Similarity |
NPD2489 |
Approved |
0.6685 |
Remote Similarity |
NPD27 |
Approved |
0.6685 |
Remote Similarity |
NPD6801 |
Discontinued |
0.6683 |
Remote Similarity |
NPD7696 |
Phase 3 |
0.6683 |
Remote Similarity |
NPD7697 |
Approved |
0.6683 |
Remote Similarity |
NPD7698 |
Approved |
0.6667 |
Remote Similarity |
NPD4160 |
Clinical (unspecified phase) |
0.6667 |
Remote Similarity |
NPD3496 |
Discontinued |
0.6667 |
Remote Similarity |
NPD3051 |
Approved |
0.6667 |
Remote Similarity |
NPD2797 |
Approved |
0.6667 |
Remote Similarity |
NPD4978 |
Clinical (unspecified phase) |
0.6667 |
Remote Similarity |
NPD7229 |
Phase 3 |
0.6667 |
Remote Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.6667 |
Remote Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.665 |
Remote Similarity |
NPD8319 |
Approved |
0.665 |
Remote Similarity |
NPD8320 |
Phase 1 |
0.6649 |
Remote Similarity |
NPD8150 |
Discontinued |
0.6649 |
Remote Similarity |
NPD4663 |
Approved |
0.6648 |
Remote Similarity |
NPD6818 |
Clinical (unspecified phase) |
0.6647 |
Remote Similarity |
NPD230 |
Phase 1 |
0.6645 |
Remote Similarity |
NPD3022 |
Approved |
0.6645 |
Remote Similarity |
NPD3021 |
Approved |
0.6634 |
Remote Similarity |
NPD7701 |
Phase 2 |
0.663
|
Remote Similarity |
NPD7832 |
Clinical (unspecified phase) |